Daclatasvir: potential role in hepatitis C
Open Access
- 1 October 2013
- journal article
- review article
- Published by Taylor & Francis Ltd in Drug Design, Development and Therapy
- Vol. 7, 1223-33
- https://doi.org/10.2147/DDDT.S40310
Abstract
Peer reviewed article authored by (Lee C). Read article or submit your manuscript for publishing.Keywords
This publication has 51 references indexed in Scilit:
- Sofosbuvir-based interferon-free therapy for patients with HCV infectionJournal of Hepatology, 2013
- Pulmonary complications of treatment with pegylated interferon for hepatitis C infection-Two case reportsAnnals of Hepatology, 2013
- Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future PerspectivesThe Scientific World Journal, 2013
- In Vitro Activity of Daclatasvir on Hepatitis C Virus Genotype 3 NS5AAntimicrobial Agents and Chemotherapy, 2013
- Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevirJournal of Hepatology, 2012
- Prevalence of Natural Polymorphisms at the HCV Ns5A Gene Associated with Resistance to Daclatasvir, An Ns5A InhibitorAntiviral Therapy, 2012
- Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trialThe Lancet Infectious Diseases, 2012
- Hepatitis C Virus RNA Elimination and Development of Resistance in Replicon Cells Treated with BMS-790052Antimicrobial Agents and Chemotherapy, 2012
- The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localizationJournal of General Virology, 2011
- Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicaseNature, 2005